255 related articles for article (PubMed ID: 37231356)
21. A Differentiation-Related Gene Prognostic Index Contributes to Prognosis and Immunotherapy Evaluation in Patients with Hepatocellular Carcinoma.
Xiao J; Liu T; Liu Z; Xiao C; Du J; Zuo S; Li H; Gu H
Cells; 2022 Jul; 11(15):. PubMed ID: 35892599
[TBL] [Abstract][Full Text] [Related]
22. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
23. A pyrimidine metabolism-related signature for prognostic and immunotherapeutic response prediction in hepatocellular carcinoma by integrating analyses.
Zhang S; Qin O; Wu S; Xu H; Huang W; Hailiang S
Aging (Albany NY); 2024 Mar; 16(6):5545-5566. PubMed ID: 38517376
[TBL] [Abstract][Full Text] [Related]
24. Development of a macrophages-related 4-gene signature and nomogram for the overall survival prediction of hepatocellular carcinoma based on WGCNA and LASSO algorithm.
Yang Z; Zi Q; Xu K; Wang C; Chi Q
Int Immunopharmacol; 2021 Jan; 90():107238. PubMed ID: 33316739
[TBL] [Abstract][Full Text] [Related]
25. Identification of a novel histone phosphorylation prognostic signature in hepatocellular carcinoma based on bulk and single-cell RNA sequencing.
Fan L; Xu L; Tian S; Zheng X
Front Endocrinol (Lausanne); 2022; 13():965445. PubMed ID: 36120466
[TBL] [Abstract][Full Text] [Related]
26. A novel natural killer-related signature to effectively predict prognosis in hepatocellular carcinoma.
Xi D; Wang J; Yang Y; Ji F; Li C; Yan X
BMC Med Genomics; 2023 Sep; 16(1):211. PubMed ID: 37674210
[TBL] [Abstract][Full Text] [Related]
27. Deciphering the immune heterogeneity dominated by natural killer cells with prognostic and therapeutic implications in hepatocellular carcinoma.
Guo C; Tang Y; Li Q; Yang Z; Guo Y; Chen C; Zhang Y
Comput Biol Med; 2023 May; 158():106872. PubMed ID: 37030269
[TBL] [Abstract][Full Text] [Related]
28. Deciphering a mitochondria-related signature to supervise prognosis and immunotherapy in hepatocellular carcinoma.
Shi Y; Huang G; Jiang F; Zhu J; Xu Q; Fang H; Lan S; Pan Z; Jian H; Li L; Zhang Y
Front Immunol; 2022; 13():1070593. PubMed ID: 36544763
[TBL] [Abstract][Full Text] [Related]
29. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.
Zhang G; Zhang K; Zhao Y; Yang Q; Lv X
BMC Cancer; 2022 Oct; 22(1):1103. PubMed ID: 36307751
[TBL] [Abstract][Full Text] [Related]
30. Integration of single-cell RNA-seq and bulk RNA-seq to construct liver hepatocellular carcinoma stem cell signatures to explore their impact on patient prognosis and treatment.
Liu L; Zhang M; Cui N; Liu W; Di G; Wang Y; Xi X; Li H; Shen Z; Gu M; Wang Z; Jiang S; Liu B
PLoS One; 2024; 19(4):e0298004. PubMed ID: 38635528
[TBL] [Abstract][Full Text] [Related]
31. Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma.
Zhao J; Luo Z; Fu R; Zhou J; Chen S; Wang J; Chen D; Xie X
Eur J Med Res; 2023 Dec; 28(1):571. PubMed ID: 38057871
[TBL] [Abstract][Full Text] [Related]
32. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
Xiong X; Song Q; Jing M; Yan W
Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
[TBL] [Abstract][Full Text] [Related]
33. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on NK cell marker genes to predict prognosis and immunotherapy response in hepatocellular carcinoma.
Yang D; Zhao F; Su Y; Zhou Y; Shen J; Yu B; Zhao K; Ding Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10609-10621. PubMed ID: 37296316
[TBL] [Abstract][Full Text] [Related]
34. A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma.
Yang Z; Li X; Pan C; Li Y; Lin L; Jin Y; Zheng J; Yu Z
BMC Cancer; 2022 Dec; 22(1):1344. PubMed ID: 36550445
[TBL] [Abstract][Full Text] [Related]
35. A novel liver zonation phenotype-associated molecular classification of hepatocellular carcinoma.
Zhang T; Gu J; Wang X; Lu Y; Cai K; Li H; Nie Y; Chen X; Wang J
Front Immunol; 2023; 14():1140201. PubMed ID: 36936935
[TBL] [Abstract][Full Text] [Related]
36. A necroptosis-related gene signature for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma.
Chen J; Wang H; Zhou L; Liu Z; Chen H; Tan X
Cancer Med; 2022 Dec; 11(24):5079-5096. PubMed ID: 35560794
[TBL] [Abstract][Full Text] [Related]
37. Integrated analysis revealing a novel stemness-metabolism-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma.
Wang Y; Wan X; Du S
Front Immunol; 2023; 14():1100100. PubMed ID: 37622118
[TBL] [Abstract][Full Text] [Related]
38. A novel tumor immunotherapy-related signature for risk stratification, prognosis prediction, and immune status in hepatocellular carcinoma.
Sun J; Xi L; Zhang D; Gao F; Wang L; Yang G
Sci Rep; 2023 Oct; 13(1):18709. PubMed ID: 37907783
[TBL] [Abstract][Full Text] [Related]
39. Combined analysis of bulk and single-cell RNA sequencing reveals novel natural killer cell-related prognostic biomarkers for predicting immunotherapeutic response in hepatocellular carcinoma.
Zhang K; Yuan E
Front Immunol; 2023; 14():1142126. PubMed ID: 37056756
[TBL] [Abstract][Full Text] [Related]
40. An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.
Yao N; Jiang W; Wang Y; Song Q; Cao X; Zheng W; Zhang J
Eur J Med Res; 2023 Mar; 28(1):123. PubMed ID: 36918943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]